Virtually Observed Treatment (VOT) for TB Patients in The Republic of Moldova
How to cite
Kettle, Stewart; Ravenscroft, Luke. 2014. "Virtually Observed Treatment (VOT) for TB Patients in The Republic of Moldova." AEA RCT Registry. AEARCTR-0000579. https://doi.org/10.1257/rct.579-4.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
This trial aims to increase the wellbeing of tuberculosis patients and their adherence to medication in Chisinau, The Republic of Moldova. The design is an individually randomised controlled trial (RCT) and will involve 200 TB patients during their ‘continuation phase’ of treatment. The trial will have two arms; 100 patients will form the control group and receive the standard provision of Directly Observed Treatment (DOT) and 100 will receive Virtually Observed Treatment (VOT). VOT differs from DOT in that the daily observation of patients taking their medication will be observed via internet video calling rather than in-person. Based on a small sample of patient interviews we think that for some patients DOT may be a hindrance rather than a help. VOT allows patients to take their treatment in the comfort of their home and means they don’t have to travel to their polyclinic every day. The trial design will be implemented by Act for Involvement (AFI) and the Ministry of Health in Moldova. The trial will be available to patients that have access to a computer, smartphone or any device that can run Skype. Two VOT observation centres will be set up; one at AFI and one in an existing polyclinic. The trial duration will dependent on the number of eligible patients but is expected to take 16 months.
Intervention
The Republic of Moldova has one of the highest documented levels of MDR-TB in the world (WHO, 2013) . The Ministry of Health has followed the WHO-recommended DOT (Directly Observed Treatment) during 2000-2004 and has used the Stop TB Strategy which includes DOT since 2006 (WHO, 2013). DOT is recommended by WHO as the best curative method for TB. Based on a small sample of patient interviews we think that for some patients DOT may be a hindrance rather than a help. The way that DOT is currently implemented in Moldova means that patients have to visit a doctor or nurse every day in order to be observed taking treatment. This is time consuming, can cost patients money, and adds a significant friction cost for patients. The alternative, for DOTs to be administered at home by roving personnel, is resource intensive and currently only available to a small number of patients in Moldova. VOT differs from DOT in that the daily observation of patients taking their medication will be observed via internet video calling rather than in-person. This should save patients a huge amount of time and money. Given the prevalence of side effects of medication, being able to take medication at home may also increase patient wellbeing.
Experimental design
The trial will work as a consent-randomise individually randomised trial. Initially patients in the intensive phase in Chisinau will be questioned in order to determine their eligibility to take part in the trial based on certain criteria. Patients that meet the criteria will then be given information on the trial and decide whether they want to participate. Those that meet the eligibility criteria and give consent will be randomised into receiving VOT or DOT.
Design details
Cited by
No citation data available for this registration yet.